VERTEX PHARMACEUTICALS INC / MA — Key Metrics
3 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Beat / Miss vs Estimate
Stock Price on Earnings Dates
VERTEX PHARMACEUTICALS INC / MA — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 0.60% | 0.80% | 0.60% | 0.30% | 29.50% | 0.00% |
| Foreign Rate Differential | 0.20% | -0.30% | -0.30% | -0.60% | 21.30% | — |
| Other Adjustments | 1.10% | 0.70% | 0.00% | 1.10% | 27.90% | — |
| R&D Tax Credits | — | — | — | — | — | 3.30% |
| FDII Deduction | 0.20% | 0.80% | 1.40% | 1.70% | 28.30% | 1.30% |
| SBC (Nondeductible) | -2.30% | 0.00% | -0.80% | -0.80% | -25.50% | — |
| Tax Law Change | -1.20% | -3.50% | 0.00% | 0.00% | — | — |
| Effective Tax Rate | 13.00% | 14.20% | 21.50% | 17.40% | 3.15% | 14.90% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $405.2M | $388.3M | $910.4M | $760.2M | $784.1M | $690.0M |
| Income Taxes Paid (Cash) | $191.8M | $476.3M | $1.06B | $1.68B | $1.08B | $1.57B |